Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) and Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Valuation and Earnings
This table compares Quoin Pharmaceuticals and Alaunos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quoin Pharmaceuticals | N/A | N/A | -$15.81 million | ($29.56) | -0.15 |
| Alaunos Therapeutics | N/A | N/A | -$4.18 million | ($2.13) | -1.11 |
Analyst Ratings
This is a summary of current ratings and target prices for Quoin Pharmaceuticals and Alaunos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quoin Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Alaunos Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Quoin Pharmaceuticals and Alaunos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quoin Pharmaceuticals | N/A | -489.85% | -221.29% |
| Alaunos Therapeutics | N/A | -165.94% | -123.50% |
Volatility and Risk
Quoin Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its stock price is 207% less volatile than the S&P 500.
Summary
Alaunos Therapeutics beats Quoin Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
